Zobrazeno 1 - 10 of 16 pro vyhledávání: '"Aurea Molina"'
1
Akademický článek
Outcomes and patterns of use of Radium-223 in metastatic castration-resistant prostate cancer
Autor: Urbano Anido-Herranz, Ovidio Fernandez-Calvo, Juan Ruiz-Bañobre, Sara Martinez-Breijo, Natalia Fernandez-Nuñez, Zulema Nogareda-Seoane, Miguel Garrido-Pumar, Javier Casas-Nebra, Gloria Muñiz-Garcia, Paula Portela-Pereira, Antonio Gomez-Caamaño, Daniel Adolfo Perez-Fentes, Lucia Santome-Couto, Martín Lázaro, Aurea Molina-Diaz, Ana Medina-Colmenero, Sergio Vazquez-Estevez
Publikováno v: Frontiers in Oncology, Vol 14 (2024)
IntroductionRadium-223 dichloride (Ra-223) is recommended as a treatment option for metastatic castration-resistant prostate cancer (mCRPC) patients with symptomatic bone metastases and no visceral disease, after docetaxel failure, or in patients who
Externí odkaz: https://doaj.org/article/54152fa9facb47b9970ec092bda4d1a6
Zobrazit plný text záznamu
2
Real-world Data of Paclitaxel and Cetuximab in Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck
Autor: SANTIAGO AGUIN, ALBERTO CARRAL, LETICIA IGLESIAS, CAROLINA PENA, AUREA MOLINA, MARINHA COSTA, MARTA COVELA, JESUS GARCIA GOMEZ, RAMÓN GARCIA ARROYO, GERARDO HUIDOBRO, ROCÍO VILCHES SIMO, ANA MEDINA
Publikováno v: Cancer Diagn Progn
Background/Aim: Prior immune-checkpoint inhibitors, weekly paclitaxel-cetuximab was one of the few options for platinum-ineligible patients with recurrent/ metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN). This real-world study ana
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8ca9e65dce1e059f18c814a6b5719ef
https://europepmc.org/articles/PMC9949534/
Zobrazit plný text záznamu
3
Is there a correlation between HER2 gene amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2-positive breast cancer?
Autor: Cristina Reboredo, Lucía García-Caballero, Ángel Vázquez-Boquete, Ángel Concha, Mari Paz Santiago, Aurea Molina, Tomás García-Caballero, Silvia Antolín, Eva Pérez, Lourdes Calvo, Rosalía Gallego, Joaquín Mosquera
Publikováno v: Virchows Archiv. 479:853-857
There are contradictory data regarding the correlation between HER2 amplification level determined by in situ hybridization and evolution after treatment with anti-HER2 therapies. The aim of this study was to correlate quantitative results of FISH (r
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a76c2bc10270e47465677cc689b762c3
https://doi.org/10.1007/s00428-021-03104-7
Zobrazit plný text záznamu
6
Abstract P1-15-17: Liposomal-encapsulated doxorubicin (Myocet)as part of primary systemic therapy in HER2-positive operable breast cancer: Efficacy data, cardiotoxicity and long-term follow-up in 81 patients diagnosed from 2005-2016 at a single institution
Autor: Lourdes Calvo, J. Prato, Silvia Antolín, Aurea Molina, Cristina Reboredo, Joaquín Mosquera
Publikováno v: Cancer Research. 79:P1-15
Objectives To evaluate the efficacy, cardiotoxicity profile and long-term benefits of liposomal doxorubicin (Myocet) as part of neoadjuvant therapy in HER2-positive operable breast cancer patients. Methods The treatment consisted of a sequential regi
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::56c448c5c4eccd3c57680dde8d25e743
https://doi.org/10.1158/1538-7445.sabcs18-p1-15-17
Zobrazit plný text záznamu
8
Correlation between HER2 amplification level and response to neoadjuvant treatment with trastuzumab and chemotherapy in HER2 positive breast cancer
Autor: Aurea Molina Diaz, Joaquín Mosquera, Maria Eva Perez, Lourdes Calvo, Ángel Vázquez-Boquete, Lucía García-Caballero, Silvia Antolín, Maria Paz Santiago, Cristina Reboredo, Ángel Concha, Rosalía Gallego, Tomás García-Caballero
Publikováno v: Journal of Clinical Oncology. 38:e12641-e12641
e12641 Background: HER2 targeted therapy in combination with chemotherapy have changed the aggressive natural history of HER2-positive tumors. To select patients to be treated with this type of agents, determination of HER2 status is usually carried
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::f09dc5e3316e53982513bf73a7d8379c
https://doi.org/10.1200/jco.2020.38.15_suppl.e12641
Zobrazit plný text záznamu
9
Socio-demographic characteristics and quality of life analysis of cancer survivors followed at a primary care center
Autor: I. Gomez-Randulfe, B. Graña Suarez, Joaquín Mosquera, M. Deben, Cristina Reboredo, Aurea Molina, P. Cordeiro, M. Lado, M. Forjan, R. Liste, A. Martinez, O. Coroas
Publikováno v: Annals of Oncology. 30:v834
Background In Spain, we do not have real-time information about cancer survivors follow-up by their family doctor. The main objective of this study is to describe the characteristics and quality of life of cancer survivors followed at a primary care
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c91deb20e3f6bf8155cfec9d0aa31a2f
https://doi.org/10.1093/annonc/mdz275.019
Zobrazit plný text záznamu
10
Incidental early occult ovarian cancer after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers followed in a community public hospital
Autor: Patricia Cordeiro, Aurea Molina, M. Quindos, Lourdes Calvo, B. Graña Suarez, J. Prato, C. Conde, E. Pérez, C. Czestokowa, I. Gomez-Randulfe, R Lesta Mellid, Silvia Antolín, C. Reboredo Rendo
Publikováno v: Annals of Oncology. 30:v414
Background Carriers of germline BRCA1/2 mutations are at high risk of developing ovarian, tubal or peritoneal cancer. Actually, risk-reducing bilateral salpingo-oophorectomy (RRSO) is the only definite preventive strategy. The aim of this study is to
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::76d99f128f3c8daf5632cfbf9373bec0
https://doi.org/10.1093/annonc/mdz250.021
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje